AstraZeneca (LON:AZN) Given “Buy” Rating at Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Shore Capital in a report released on Thursday, Digital Look reports.

AZN has been the subject of several other reports. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Monday, September 16th. Berenberg Bank reaffirmed a “buy” rating and issued a £150 ($195.26) price objective on shares of AstraZeneca in a research note on Monday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($143.19) target price on shares of AstraZeneca in a report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of £101.62 ($132.29).

AstraZeneca Stock Performance

Shares of LON:AZN traded down GBX 150 ($1.95) during trading on Thursday, hitting GBX 9,772 ($127.21). The company’s stock had a trading volume of 44,883,191 shares, compared to its average volume of 4,123,456. The company has a 50-day moving average of £120.21 and a 200-day moving average of £121.65. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a market cap of £151.47 billion, a price-to-earnings ratio of 3,102.22, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12 month low of GBX 9,461 ($123.16) and a 12 month high of £133.88 ($174.28).

Insider Activity

In other news, insider Michel Demare bought 2,000 shares of the stock in a transaction dated Friday, September 13th. The stock was purchased at an average price of GBX 118 ($1.54) per share, for a total transaction of £2,360 ($3,072.12). Company insiders own 0.04% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.